NASDAQ:TROV - Cardiff Oncology Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.05 (-0.93%)
Get New Cardiff Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TROV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TROV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.31.

This chart shows the closing price for TROV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Cardiff Oncology. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/28/2020Noble FinancialReiterated RatingOutperformMedium
10/3/2019Maxim GroupReiterated RatingBuy$6.00Low
10/2/2019Noble FinancialReiterated RatingBuy$23.00Low
8/28/2019Noble FinancialReiterated RatingBuy$23.00Low
8/9/2019Maxim GroupReiterated RatingBuy$6.00Medium
7/31/2019Maxim GroupSet Price TargetBuy$6.00N/A
5/24/2019Noble FinancialSet Price TargetBuy$23.00Low
5/23/2019Maxim GroupSet Price TargetBuy$8.00Low
5/10/2019Noble FinancialSet Price TargetBuy$5.00Medium
5/8/2019Maxim GroupSet Price TargetBuy$8.00Medium
4/2/2019Maxim GroupSet Price TargetBuy$8.00Low
3/8/2019Noble FinancialSet Price TargetOutperform$27.00 ➝ $20.00High
3/7/2019Maxim GroupReiterated RatingBuy$8.00High
3/1/2019Maxim GroupBoost Price TargetPositive ➝ Buy$8.00 ➝ $18.00High
2/21/2019Noble FinancialReiterated RatingBuyMedium
2/1/2019Noble FinancialReiterated RatingBuyLow
1/7/2019Noble FinancialInitiated CoverageOutperform$31.20High
8/6/2018Maxim GroupReiterated RatingBuyLow
6/15/2018Maxim GroupUpgradeHold ➝ BuyHigh
6/4/2018HC WainwrightSet Price TargetBuy$42.00N/A
5/9/2018Maxim GroupReiterated RatingHoldLow
4/16/2018Maxim GroupReiterated RatingHoldHigh
3/6/2018HC WainwrightReiterated RatingBuy$72.00High
3/5/2018Maxim GroupReiterated RatingHoldHigh
1/24/2018Maxim GroupReiterated RatingHoldMedium
12/21/2017HC WainwrightInitiated CoverageBuy$72.00High
11/10/2017Maxim GroupDowngradeBuy ➝ HoldN/A
10/18/2017Maxim GroupSet Price TargetBuy$288.00N/A
8/22/2017Maxim GroupSet Price TargetBuy$288.00Medium
8/16/2017Maxim GroupSet Price TargetBuy$288.00High
8/10/2017Maxim GroupSet Price TargetBuy$288.00Low
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHigh
7/27/2017Maxim GroupSet Price TargetBuy$288.00High
7/6/2017Maxim GroupSet Price TargetBuy$288.00High
6/27/2017Maxim GroupSet Price TargetBuy$288.00Low
6/13/2017Maxim GroupReiterated RatingBuy$288.00Low
5/25/2017Maxim GroupSet Price TargetBuy$288.00High
5/11/2017Maxim GroupSet Price TargetBuy$288.00High
5/5/2017Maxim GroupReiterated RatingBuy$288.00Low
4/12/2017Maxim GroupUpgradeHold ➝ Buy$288.00Medium
3/18/2017Cantor FitzgeraldSet Price TargetBuy$576.00High
3/16/2017Maxim GroupDowngradeBuy ➝ HoldHigh
3/16/2017Piper Jaffray CompaniesDowngradeNeutral ➝ UnderweightHigh
3/10/2017S&P Equity ResearchBoost Price Target$111.60 ➝ $129.60N/A
12/14/2016Cantor FitzgeraldSet Price TargetBuy$576.00N/A
11/30/2016Cantor FitzgeraldReiterated RatingBuyN/A
11/10/2016Cantor FitzgeraldReiterated RatingBuy$576.00N/A
10/6/2016Maxim GroupReiterated RatingBuy$648.00N/A
8/8/2016Cantor FitzgeraldUpgradeHold ➝ Buy$360.00 ➝ $504.00N/A
8/5/2016Piper Jaffray CompaniesSet Price TargetHold$360.00 ➝ $288.00N/A
8/5/2016Maxim GroupBoost Price TargetBuy$648.00 ➝ $864.00N/A
(Data available from 7/24/2016 forward)
Cardiff Oncology logo
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $5.31
Low: $5.10
High: $5.52

50 Day Range

MA: $16.75
Low: $1.19
High: $24.71

52 Week Range

Now: $5.31
Low: $0.70
High: $3.46


956,823 shs

Average Volume

648,892 shs

Market Capitalization

$58.47 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiff Oncology?

The following sell-side analysts have issued reports on Cardiff Oncology in the last twelve months:
View the latest analyst ratings for TROV.

What is the current price target for Cardiff Oncology?

0 Wall Street analysts have set twelve-month price targets for Cardiff Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cardiff Oncology in the next year.
View the latest price targets for TROV.

What is the current consensus analyst rating for Cardiff Oncology?

Cardiff Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TROV.

What other companies compete with Cardiff Oncology?

How do I contact Cardiff Oncology's investor relations team?

Cardiff Oncology's physical mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company's listed phone number is (858) 952-7570 and its investor relations email address is [email protected] The official website for Cardiff Oncology is